Hyloris Pharmaceuticals SA
XBRU:HYL
Income Statement
Earnings Waterfall
Hyloris Pharmaceuticals SA
Revenue
|
2.8m
EUR
|
Cost of Revenue
|
-93k
EUR
|
Gross Profit
|
2.7m
EUR
|
Operating Expenses
|
-18.8m
EUR
|
Operating Income
|
-16.1m
EUR
|
Other Expenses
|
327k
EUR
|
Net Income
|
-15.8m
EUR
|
Income Statement
Hyloris Pharmaceuticals SA
Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue |
1
N/A
|
3
+233%
|
3
+6%
|
2
-41%
|
3
+59%
|
3
-10%
|
|
Gross Profit | |||||||
Cost of Revenue |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Gross Profit |
1
N/A
|
3
+250%
|
3
+6%
|
2
-41%
|
3
+60%
|
3
-8%
|
|
Operating Income | |||||||
Operating Expenses |
(11)
|
(13)
|
(10)
|
(13)
|
(21)
|
(19)
|
|
Selling, General & Administrative |
(1)
|
(3)
|
(3)
|
(4)
|
(6)
|
(6)
|
|
Research & Development |
(4)
|
(5)
|
(8)
|
(10)
|
(17)
|
(15)
|
|
Other Operating Expenses |
(5)
|
(5)
|
0
|
0
|
2
|
2
|
|
Operating Income |
(10)
N/A
|
(10)
-6%
|
(7)
+29%
|
(12)
-57%
|
(19)
-61%
|
(16)
+13%
|
|
Pre-Tax Income | |||||||
Interest Income Expense |
(2)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
|
Non-Reccuring Items |
0
|
(0)
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
Pre-Tax Income |
(12)
N/A
|
(11)
+3%
|
(8)
+29%
|
(12)
-47%
|
(18)
-56%
|
(16)
+14%
|
|
Net Income | |||||||
Tax Provision |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
Income from Continuing Operations |
(12)
|
(12)
|
(8)
|
(12)
|
(18)
|
(16)
|
|
Net Income (Common) |
(12)
N/A
|
(12)
+1%
|
(8)
+28%
|
(12)
-42%
|
(18)
-56%
|
(16)
+14%
|
|
EPS (Diluted) |
-0.45
N/A
|
-0.45
N/A
|
-0.32
+29%
|
-0.43
-34%
|
-0.68
-58%
|
-0.58
+15%
|